![UniQure, with sale of plant, outsources Hemgenix manufacturing](https://www.biopharmadive.com/imgproxy/Dn2QC-0kAfq_NJgg0o3w-EaA-bIAcuY-bOmLdc5kyKk/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlLzRjZDA0ZTVhLWU2YTItNDY5ZS04ZWQxLWY4ZmE3YzMzODlhZS5qcGVn.webp)
UniQure, with sale of plant, outsources Hemgenix manufacturing
Dive Brief: UniQure will sell a gene therapy production plant in Lexington, Massachusetts, to contract manufacturer Genezen in a deal designed to reduce the biotechnology company’s operating expenses. Genezen will pay UniQure $25 million in stock and debt for the facility, as well as offer employment to the “majority” of UniQure staff currently working at…